We are Dipropylamine CAS:142-84-7 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
CAS No: 142-84-7
Product Name: Dipropylamine
Density: 0.7±0.1 g/cm3
Boiling Point: 108.8±0.0 °C at 760 mmHg
Melting Point: -63 °C
Molecular Formula: C6H15N
Molecular Weight: 101.190
Flash Point: 3.9±0.0 °C
Exact Mass: 101.120445
Vapour Pressure: 25.5±0.2 mmHg at 25°C
Index of Refraction: 1.405
Stability: Stable. Highly flammable. Incompatible with strong oxidizing agents.
Water Solubility: soluble
Appearance: Colorless transparent liquid
Intermediates of Vernolate CAS: 1929-77-7.
Intermediates of Eradicane CAS: 759-94-4.
Intermediates of Thiobencarb CAS: 28249-77-6.
Intermediates of Oryzalin CAS: 19044-88-3.
Intermediates of Trifluralin CAS: 1582-09-8.
For organic synthetic raw materials. Applicationd in the preparation of pesticides, medicines (dipropyl glutamine, etc.), boiler preservatives, engine coolants, lubricating oils, metal cutting oils, decarbonizers, corrosion lubricants and emulsifiers, and solvents. Pesticides are the most important use.
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Related News: Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. N4-isobutilquinolina-3,4-diamina CAS:99010-09-0 Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.4-chloropyridine-2-carbonitrile CAS:19235-89-3 What is the difference? Raw material refers to chemical compounds that are used as a base to make an API.81-07-2 What is the difference? Raw material refers to chemical compounds that are used as a base to make an API.In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired.